Iradimed Corp (NASDAQ:IRMD) VP Sells $138,120.00 in Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 6,000 shares of Iradimed stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.02, for a total transaction of $138,120.00. Following the completion of the sale, the vice president now directly owns 7,368 shares of the company’s stock, valued at $169,611.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Brent Johnson also recently made the following trade(s):

  • On Friday, November 8th, Brent Johnson sold 6,000 shares of Iradimed stock. The shares were sold at an average price of $23.06, for a total transaction of $138,360.00.
  • On Friday, November 1st, Brent Johnson sold 4,000 shares of Iradimed stock. The shares were sold at an average price of $24.98, for a total transaction of $99,920.00.
  • On Wednesday, October 30th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $24.41, for a total transaction of $73,230.00.
  • On Monday, October 28th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $23.80, for a total transaction of $47,600.00.
  • On Friday, October 25th, Brent Johnson sold 4,000 shares of Iradimed stock. The stock was sold at an average price of $23.81, for a total transaction of $95,240.00.
  • On Wednesday, October 23rd, Brent Johnson sold 4,000 shares of Iradimed stock. The stock was sold at an average price of $23.78, for a total transaction of $95,120.00.
  • On Monday, October 21st, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $23.00, for a total transaction of $46,000.00.
  • On Friday, October 18th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $22.90, for a total transaction of $45,800.00.
  • On Wednesday, October 16th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $21.92, for a total transaction of $65,760.00.
  • On Monday, October 14th, Brent Johnson sold 1,902 shares of Iradimed stock. The stock was sold at an average price of $21.82, for a total transaction of $41,501.64.

Iradimed stock traded down $0.38 during midday trading on Friday, hitting $23.11. 35,200 shares of the stock were exchanged, compared to its average volume of 72,107. Iradimed Corp has a 52-week low of $16.68 and a 52-week high of $30.90. The stock has a market capitalization of $274.60 million, a price-to-earnings ratio of 53.74 and a beta of 1.60. The business’s 50-day moving average price is $22.84 and its 200-day moving average price is $21.51. The company has a quick ratio of 9.05, a current ratio of 9.82 and a debt-to-equity ratio of 0.05.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.07. Iradimed had a net margin of 22.51% and a return on equity of 16.24%. The business had revenue of $9.96 million for the quarter, compared to analysts’ expectations of $9.85 million. On average, sell-side analysts predict that Iradimed Corp will post 0.7 earnings per share for the current fiscal year.

Several research firms have recently commented on IRMD. BidaskClub raised shares of Iradimed from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Saturday, October 26th. Finally, ValuEngine upgraded shares of Iradimed from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th.

A number of institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its holdings in Iradimed by 109.3% during the third quarter. Tower Research Capital LLC TRC now owns 2,024 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 1,057 shares during the last quarter. Strs Ohio boosted its holdings in Iradimed by 7.5% during the second quarter. Strs Ohio now owns 20,100 shares of the medical equipment provider’s stock worth $411,000 after purchasing an additional 1,400 shares during the last quarter. Morgan Stanley boosted its holdings in Iradimed by 14.3% during the second quarter. Morgan Stanley now owns 13,118 shares of the medical equipment provider’s stock worth $268,000 after purchasing an additional 1,637 shares during the last quarter. Northern Trust Corp boosted its holdings in Iradimed by 2.5% during the second quarter. Northern Trust Corp now owns 73,296 shares of the medical equipment provider’s stock worth $1,499,000 after purchasing an additional 1,765 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Iradimed by 34.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 10,500 shares of the medical equipment provider’s stock worth $215,000 after purchasing an additional 2,666 shares during the last quarter. Institutional investors and hedge funds own 30.57% of the company’s stock.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Recommended Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit